Development and Evaluation of a Genomic Signature for the Prediction and Mechanistic Assessment of Nongenotoxic Hepatocarcinogens in the Rat (original) (raw)

Journal Article

Mark R. Fielden ,

*Comparative Biology and Safety Sciences, Amgen, South San Francisco, California 94080

1To whom correspondence should be addressed at Comparative Biology and Safety Sciences, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080. Fax: (650) 837-9631. E-mail: [email protected].

Search for other works by this author on:

Alex Adai ,

†Asuragen, Austin, Texas 78744

Search for other works by this author on:

Robert T. Dunn, II ,

‡Comparative Biology and Safety Sciences, Amgen, Thousand Oaks, California 91320

Search for other works by this author on:

Andrew Olaharski ,

§Non-Clinical Safety, Roche, Nutley, New Jersey 07110

Search for other works by this author on:

George Searfoss ,

¶Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285

Search for other works by this author on:

Joe Sina ,

‖Merck Research Laboratories, West Point, Pennsylvania 19486

Search for other works by this author on:

Jiri Aubrecht ,

‖|Pfizer, Groton, Connecticut 06340

Search for other works by this author on:

Eric Boitier ,

‖‖Sanofi-aventis R&D, Vitry sur Seine, France

Search for other works by this author on:

Paul Nioi ,

#Schering-Plough Research Institute, Summit, New Jersey 08854

2

Present address: Comparative Biology and Safety Sciences, Amgen, Thousand Oaks, CA 91320

Search for other works by this author on:

Scott Auerbach

**National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27703

Search for other works by this author on:

on behalf of the Predictive Safety Testing Consortium, Carcinogenicity Working Group

... Show more

Published:

02 August 2011

Cite

Mark R. Fielden, Alex Adai, Robert T. Dunn, Andrew Olaharski, George Searfoss, Joe Sina, Jiri Aubrecht, Eric Boitier, Paul Nioi, Scott Auerbach, David Jacobson-Kram, Nandini Raghavan, Yi Yang, Andrew Kincaid, Jon Sherlock, Shen-Jue Chen, Bruce Car, on behalf of the Predictive Safety Testing Consortium, Carcinogenicity Working Group, Development and Evaluation of a Genomic Signature for the Prediction and Mechanistic Assessment of Nongenotoxic Hepatocarcinogens in the Rat, Toxicological Sciences, Volume 124, Issue 1, November 2011, Pages 54–74, https://doi.org/10.1093/toxsci/kfr202
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Evaluating the risk of chemical carcinogenesis has long been a challenge owing to the protracted nature of the pathology and the limited translatability of animal models. Although numerous short-term in vitro and in vivo assays have been developed, they have failed to reliably predict the carcinogenicity of nongenotoxic compounds. Extending upon previous microarray work (Fielden, M. R., Nie, A., McMillian, M., Elangbam, C. S., Trela, B. A., Yang, Y., Dunn, R. T., II, Dragan, Y., Fransson-Stehen, R., Bogdanffy, M., et al. (2008). Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol. Sci. 103, 28–34), we have developed and extensively evaluated a quantitative PCR-based signature to predict the potential for nongenotoxic compounds to induce liver tumors in the rat as a first step in the safety assessment of potential nongenotoxic carcinogens. The training set was derived from liver RNA from rats treated with 72 compounds and used to develop a 22-gene signature on the TaqMan array platform, providing an economical and standardized assay protocol. Independent testing on over 900 diverse samples (66 compounds) confirmed the interlaboratory precision of the assay and its ability to predict known nongenotoxic hepatocarcinogens (NGHCs). When tested under different experimental designs, strains, time points, dose setting criteria, and other preanalytical processes, the signature sensitivity and specificity was estimated to be 67% (95% confidence interval [CI] = 38–88%) and 59% (95% CI = 44–72%), respectively, with an area under the receiver operating characteristic curve of 0.65 (95% CI = 0.46–0.83%). Compounds were best classified using expression data from short-term repeat dose studies; however, the prognostic expression changes appeared to be preserved after longer term treatment. Exploratory evaluations also revealed that different modes of action for nongenotoxic and genotoxic compounds can be discriminated based on the expression of specific genes. These results support a potential early preclinical testing paradigm to catalyze broader understanding of putative NGHCs.

© The Author 2011. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: [email protected]

Topic:

You do not currently have access to this article.

I agree to the terms and conditions. You must accept the terms and conditions.

Submit a comment

Name

Affiliations

Comment title

Comment

You have entered an invalid code

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Personal account

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution's website and Oxford Academic.

  1. Click Sign in through your institution.
  2. Select your institution from the list provided, which will take you to your institution's website to sign in.
  3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
  4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution's website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see "Sign in through society site" in the sign in pane within a journal:

  1. Click Sign in through society site.
  2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
  3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Development and Evaluation of a Genomic Signature for the Prediction and Mechanistic Assessment of Nongenotoxic Hepatocarcinogens in the Rat - 24 Hours access

EUR €53.00

GBP £44.00

USD $58.00

Rental

Read this now at DeepDyve

This article is also available for rental through DeepDyve.